Overview
- The definitive joint venture will research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies, including the upcoming Co-Dx PCR point-of-care platform, in KSA and 18 other MENA countries.
- Arabian Eagle will lead local operations including manufacturing facility setup, regulatory registration, logistics and compliance, while Co-Diagnostics grants CoMira an exclusive license to use, produce and commercialize the IP.
- The Co-Dx PCR platform, including PCR Home, PCR Pro, the mobile app and associated tests, remains under regulatory review and is not currently for sale.
- Clinical evaluations are being prepared to start before the end of 2025 for tuberculosis, an eight-type HPV multiplex test and an upper respiratory panel covering influenza A and B, COVID-19 and RSV.
- Co-Diagnostics recently disclosed a $10 million registered direct offering, and shares jumped intraday on the JV news, with Benzinga Pro noting a move to about $1.02, up roughly 188%.